Adial Pharmaceuticals filed a prospectus with the US Securities and Exchange Commission (SEC) related to the proposed resale of up to 25,148,970 shares of its common stock by selling stockholders.

The filing discloses the volume of shares intended for resale by existing holders. The document serves as a regulatory notification of this secondary market activity.

Filing Details

The SEC filing outlines the specific number of shares involved in the proposed transaction. No additional financial metrics or operational data were included in the provided source text.

Adial Pharmaceuticals Inc (NASDAQ: ADIL) announced an inducement grant of 307,814 shares of common stock to a new employee. The Compensation Committee approved the award on August 25, 2026, citing it as material to the individual’s decision to join the company.

The option award carries an exercise price of $5.76 per share, reflecting the closing price of the company’s common stock on August 19, 2026. The grant has a ten-year term and vests over four years. Specifically, 25% of the options vest on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter, contingent on continued service.

Regulatory Context

The grant was made outside the company’s equity incentive plans. It relies on the employment inducement exception to shareholder approval provided under Nasdaq Listing Rule 5635(c)(4). This rule mandates public announcement for such awards to ensure transparency regarding equity compensation that bypasses standard shareholder voting procedures.

Strategic Shift to Inflammatory Diseases

Adial Pharmaceuticals, historically focused on addiction treatments, shifted its strategic focus following the June 2026 acquisition of Azora Therapeutics. The company now prioritizes serious inflammatory diseases, with ulcerative colitis (UC) as a key target. Its lead program, AT177, is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis with minimal systemic exposure.

Clinical Timeline

AT177 is currently in IND-enabling studies. The company has outlined a specific development roadmap:

• IND filing planned for the first half of 2027.
• Phase 1a single- and multiple-ascending-dose (SAD/MAD) clinical trial initiation planned for the second half of 2027.
• Phase 1b proof-of-concept study in UC patients to follow the Phase 1a trials.

Preclinical studies have demonstrated robust local colonic AhR activation for AT177, with markedly limited systemic exposure compared to other AhR agonists in development.